Objective: to analyze the clinical efficacy and safety of decitabine in elderly patients with acute myeloid leukemia. Methods: in this study, 40 cases of elderly patients with acute myeloid leukemia from May 2014 to J...Objective: to analyze the clinical efficacy and safety of decitabine in elderly patients with acute myeloid leukemia. Methods: in this study, 40 cases of elderly patients with acute myeloid leukemia from May 2014 to June 2019 were selected as the research objects, and they were randomly divided into two groups according to the nature of treatment. Among them, 20 cases were treated with cytarabine (control group), and the remaining 20 cases were treated with decitabine (Study Group). The efficacy and safety of the two groups were compared. Results: the remission rate of patients in the study group (95%) was higher than that in the control group (70%). The incidence of adverse reactions in study group (5%) was lower than that in control group (30%), P < 0.05. Conclusion: decitabine can effectively relieve the symptoms of the disease in elderly patients with acute myeloid leukemia, with high safety and significant efficacy.展开更多
文摘Objective: to analyze the clinical efficacy and safety of decitabine in elderly patients with acute myeloid leukemia. Methods: in this study, 40 cases of elderly patients with acute myeloid leukemia from May 2014 to June 2019 were selected as the research objects, and they were randomly divided into two groups according to the nature of treatment. Among them, 20 cases were treated with cytarabine (control group), and the remaining 20 cases were treated with decitabine (Study Group). The efficacy and safety of the two groups were compared. Results: the remission rate of patients in the study group (95%) was higher than that in the control group (70%). The incidence of adverse reactions in study group (5%) was lower than that in control group (30%), P < 0.05. Conclusion: decitabine can effectively relieve the symptoms of the disease in elderly patients with acute myeloid leukemia, with high safety and significant efficacy.
